Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
Nature Genetics2009Vol. 41(10), pp. 1105–1109
Citations Over TimeTop 1% of 2009 papers
Yasuhito Tanaka, Nao Nishida, Masaya Sugiyama, Masayuki Kurosaki, Kentaro Matsuura, Naoya Sakamoto, Mina Nakagawa, Masaaki Korenaga, Keisuke Hino, Shuhei Hige, Yoshito Ito, Eiji Mita, Eiji Tanaka, Satoshi Mochida, Yoshikazu Murawaki, Masao Honda, Akito Sakai, Yoichi Hiasa, Shuhei Nishiguchi, Asako Koike, Isao Sakaida, Masatoshi Imamura, Kiyoaki Ito, Koji Yano, Naohiko Masaki, Fuminaka Sugauchi, Namiki Izumi, Katsushi Tokunaga, Masashi Mizokami
Related Papers
- → Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C(2009)18 cited
- → Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C(2005)5 cited
- → 576 Early detection of depressive symptoms during treatment with pegylated interferon α-2 and ribavirin in euthymic chronic hepatitis C patients(2006)
- → Dermatological Side Effects in a Patient with Hepatitis C Infection During Treatment with Pegylated Interferon/Ribavirin+Telaprevir: A Case Report(2014)
- → Pegylated Interferon, Ribavirin, and Sofosbuvir Combination versus Pegylated Interferon, Ribavirin in the Management of Chronic Hepatitis C Egyptian Patients(2017)